Generic Symjepi Availability
Last updated on May 7, 2025.
Symjepi is a brand name of epinephrine, approved by the FDA in the following formulation(s):
SYMJEPI (epinephrine - solution;intramuscular, subcutaneous)
-
Manufacturer: ADAMIS PHARMS CORP
Approval date: June 15, 2017
Strength(s): 0.3MG/0.3ML (0.3MG/0.3ML) [RLD] -
Manufacturer: ADAMIS PHARMS CORP
Approval date: September 27, 2018
Strength(s): 0.15MG/0.3ML (0.15MG/0.3ML) (discontinued) [RLD]
Is there a generic version of Symjepi available?
No. There is currently no therapeutically equivalent version of Symjepi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symjepi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Syringe devices
Patent 11,141,540
Issued: October 12, 2021
Inventor(s): Rolfs Bryan E. & Flather Mark J. & Daniels Karen K. & Moll Thomas
Assignee(s): Adamis Pharmaceuticals CorporationDescribed herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug and a stopper. The syringe is housed and/or placed in an encasement. The plunger assembly can include a plunger, an actuator, and a spacer, wherein the plunger assembly is configured to move the stopper a predetermined distance without a user touching the plunger. Methods of assembling and using the syringe devices are also described.
Patent expiration dates:
- October 20, 2036✓✓
- October 20, 2036
More about Symjepi (epinephrine)
- Check interactions
- Compare alternatives
- Reviews (1)
- Latest FDA alerts (4)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: adrenergic bronchodilators
- Breastfeeding
- En español
Patient resources
Other brands
EpiPen, Adrenalin, neffy, Auvi-Q, ... +5 more
Professional resources
Other brands
EpiPen, Adrenalin, neffy, Auvi-Q, ... +4 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.